Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients

The nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib significantly improved survival in metastatic colorectal cancer patients (mCRC). Both treatments are characterized by different treatment-related adverse events but detailed analyses of predictive side effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Unseld, Matthias, Fischöder, Sebastian, Jachs, Mathias, Drimmel, Magdalena, Siebenhüner, Alexander, Bianconi, Daniela, Kieler, Markus, Puhr, Hannah, Minichsdorfer, Christoph, Winder, Thomas, Prager, Gerald W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356853/
https://www.ncbi.nlm.nih.gov/pubmed/32517383
http://dx.doi.org/10.3390/jcm9061772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356853/
https://www.ncbi.nlm.nih.gov/pubmed/32517383
http://dx.doi.org/10.3390/jcm9061772

Ejemplares similares